Let's Talk MRSA: 20 Frequently Asked Questions
by Vemco MedEd
Designed to clarify persistent issues in serious MRSA infections that pose a threat to patient safety and add to the healthcare burden. Experts answer frequently asked questions and share their own clinical experience. This activity consists of 20 episodes that will be released weekly beginning October 4, 2010.
Episodes
-
What are the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections?
In this Episode, Dr. George G. Zhanel from University of Manitoba, Winnipeg, Canada provides insights on the short- and long-term challenges as well as advancements that will impact the management of patients with MRSA infections.
-
How can we prevent the spread of MRSA in the hospital?
In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center, San Antonio, Texas provides insights on how we can prevent the spread of MRSA in the hospital.
-
Is there a role for OPAT in the management of patients with MRSA infections?
In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center, San Antonio, Texas provides insights on the role for OPAT in the management of patients with MRSA infections.
-
Can we determine the appropriate duration of therapy for MRSA infections?
In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center, San Antonio, Texas provides insights on appropriate duration of therapy for MRSA infections.
-
What stewardship tactics can be applied to the management of MRSA infections?
In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center, San Antonio, Texas provides insights on stewardship tactics that can be applied to the management of MRSA infections.
-
Can we differentiate among newer agents for MRSA bacteremia and endocarditis?
In this Episode, Dr. James S. Lewis from University of Texas Health Sciences Center in San Antonio, Texas provides insights on differentiation among newer agents for MRSA bacteremia and endocarditis.
-
How should clinicians manage MRSA bacteremia and infective endocarditis?
Description: In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on how clinicians should manage MRSA bacteremia and infective endocarditis.
-
How can primary care physicians manage community-associated MRSA pneumonia?
In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on how primary care physicians can manage community-associated MRSA pneumonia.
-
What is the optimal treatment for MRSA nosocomial pneumonia?
In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on optimal treatment for MRSA nosocomial pneumonia.
-
What are the therapeutic options for a complicated skin or skin structure MRSA infection?
In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on therapeutic options for a complicated skin or skin structure MRSA infection.
-
How can clinicians optimally manage community-associated MRSA skin infections?
In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on optimal management of community-associated MRSA skin infections.
-
What strategies can be used to effectively manage patients with skin and soft tissue MRSA infections?
In this Episode, Dr. Thomas M. File, Jr. from Northeastern Ohio Universities College of Medicine in Rootstown, Ohio provides insights on strategies to effectively manage patients with skin and soft tissue MRSA infections.
-
When should an alternative agent to vancomycin be considered for MRSA infections?
In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights on when an alternative agent to vancomycin should be considered for MRSA infections.
-
What are the toxicity concerns associated with using vancomycin for MRSA infections?
In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights on toxicity concerns associated with vancomycin use.
-
Should therapeutic drug monitoring be considered when using vancomycin for MRSA infections?
In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights on vancomycin therapeutic drug monitoring.
-
What is the appropriate vancomycin dosing to maximize its effectiveness?
In this Episode, Dr. Scott T. Micek from Barnes-Jewish Hospital in St. Louis, Missouri provides insights on appropriate vancomycin dosing to maximize effectiveness.
-
What is vancomycin 'MIC creep'?
In this Episode, Dr. George Zhanel from University of Manitoba in Canada provides insights on vancomycin 'MIC creep', the evidence and its implications.
-
What is community-associated MRSA? How is it different from healthcare-acquired MRSA?
In this Episode, Dr. George Zhanel from University of Manitoba in Canada provides insights on community-associated MRSA and healthcare-acquired MRSA.
-
Why is the prevalence of MRSA increasing in the hospital setting?
In this Episode, Dr. George Zhanel from University of Manitoba in Canada provides insights on why the prevalence of MRSA is increasing in the hospital setting.
-
Why is MRSA such a problematic pathogen?
In this Episode, Dr. George Zhanel from University of Manitoba in Canada provides insights on why MRSA is such a problematic pathogen.
About this show
Designed to clarify persistent issues in serious MRSA infections that pose a threat to patient safety and add to the healthcare burden. Experts answer frequently asked questions and share their own clinical experience. This activity consists of 20 episodes that will be released weekly beginning October 4, 2010.
Hosted by
Vemco MedEd
Categories